Roche Sequencing Solutions, Inc. entered into an agreement to acquire Global license of double-stranded DNA from Codexis, Inc. on February 26, 2024. Under the terms of the deal, Codexis will receive upfront and technical milestone payments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 USD | +2.99% | +5.44% | +1.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.64% | 219M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Roche Sequencing Solutions, Inc. entered into an agreement to acquire Global license of double-stranded DNA from Codexis, Inc.